Foresite Capital Management I’s 10x Genomics TXG Stock Holding History

Foresite Capital Management I’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$21.4M	Hold	750,000	–	–	100%	1
2022 Q2	$33.9M	Hold	750,000	–	–	100%	1
2022 Q1	$57.1M	Hold	750,000	–	–	99.71%	1
2021 Q4	$112M	Hold	750,000	–	–	99.68%	1
2021 Q3	$109M	Hold	750,000	–	–	85.42%	1
2021 Q2	$147M	Sell	750,000 -250,000	-25%	-$45.2M	88.53%	1
2021 Q1	$181M	Sell	1,000,000 -250,000	-20%	-$43.2M	91.29%	1
2020 Q4	$177M	Sell	1,250,000 -1,500,000	-55%	-$218M	93.12%	1
2020 Q3	$343M	Sell	2,750,000 -750,000	-21%	-$78.7M	96.54%	1
2020 Q2	$313M	Sell	3,500,000 -2,288,317	-40%	-$178M	98.53%	1
2020 Q1	$361M	Sell	5,788,317 -1,447,079	-20%	-$113M	99.8%	1
2019 Q4	$552M	Buy	+7,235,396	New	+$435M	99.92%	1

Other funds holding TXG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

SIM

SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Foresite Capital Management I's TXG Position: Q3 2022 in Review

Foresite Capital Management I held its 10x Genomics (TXG) position steady in Q3 2022 at 750,000 shares worth $21.4M. The position accounts for 100% of the portfolio, ranked #1.

Foresite Capital Management I first reported a position in TXG in Q4 2019 and has held it in 12 quarters since. The position peaked at $552M in Q4 2019. 233 funds tracked by Wall St. Rank hold TXG as of Q3 2022.

Foresite Capital Management I held 750,000 shares of 10x Genomics worth $21.4M as of Q3 2022.
Foresite Capital Management I left its 10x Genomics share count unchanged in Q3 2022.
10x Genomics made up 100% of Foresite Capital Management I's portfolio in Q3 2022, its #1 holding.
Foresite Capital Management I first reported a position in 10x Genomics in Q4 2019 and has held it in 12 quarters since.
Foresite Capital Management I's 10x Genomics position peaked at $552M in Q4 2019.
233 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2022.

Based on Foresite Capital Management I's 13F filing for Q3 2022, filed 14 Nov 2022.